Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study : The Lancet Neurology
Posted on May 12, 2013 by
The Lancet Neurology, Volume 12, Issue 3, Pages 244 – 252, March 2013
Published Online: 23 January 2013
Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study
Prof Kimford J Meador MD a Corresponding AuthorEmail Address, Gus A Baker PhD b, Nancy Browning PhD c, Morris J Cohen EdD d, Rebecca L Bromley PhD e, Jill Clayton-Smith MD f, Laura A Kalayjian MD g, Andres Kanner MD h, Joyce D Liporace MD i, Page B Pennell MD j, Michael Privitera MD k, David W Loring PhD a, for the NEAD Study Group?
Summary
Background
Many women of childbearing potential take antiepileptic drugs, but the cognitive effects of fetal exposure are uncertain. We aimed to assess effects of commonly used antiepileptic drugs on cognitive outcomes in children up to 6 years of age.
Methods
In this prospective, observational, assessor-masked, multicentre study, we enrolled pregnant women with epilepsy on antiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at 25 epilepsy centres in the UK and the USA. Our primary outcome was intelligence quotient (IQ) at 6 years of age (age-6 IQ) in all children, assessed with linear regression adjusted for maternal IQ, antiepileptic drug type, standardised dose, gestational birth age, and use of periconceptional folate. We also assessed multiple cognitive domains and compared findings with outcomes at younger ages. This study is registered with ClinicalTrials.gov, number NCT00021866.
Findings
We included 305 mothers and 311 children (six twin pairs) in the primary analysis. 224 children completed 6 years of follow-up (6-year-completer sample). Multivariate analysis of all children showed that age-6 IQ was lower after exposure to valproate (mean 97, 95% CI 94?101) than to carbamazepine (105, 102?108; p=0?0015), lamotrigine (108, 105?110; p=0?0003), or phenytoin (108, 104?112; p=0?0006). Children exposed to valproate did poorly on measures of verbal and memory abilities compared with those exposed to the other antiepileptic drugs and on non-verbal and executive functions compared with lamotrigine (but not carbamazepine or phenytoin). High doses of valproate were negatively associated with IQ (r=?0?56, p<0?0001), verbal ability (r=?0?40, p=0?0045), non-verbal ability (r=?0?42, p=0?0028), memory (r=?0?30, p=0?0434), and executive function (r=?0?42, p=0?0004), but other antiepileptic drugs were not. Age-6 IQ correlated with IQs at younger ages, and IQ improved with age for infants exposed to any antiepileptic drug. Compared with a normative sample (173 [93%] of 187 children), right-handedness was less frequent in children in our study overall (185 [86%] of 215; p=0?0404) and in the lamotrigine (59 [83%] of 71; p=0?0287) and valproate (38 [79%] of 40; p=0?0089) groups. Verbal abilities were worse than non-verbal abilities in children in our study overall and in the lamotrigine and valproate groups. Mean IQs were higher in children exposed to periconceptional folate (108, 95% CI 106?111) than they were in unexposed children (101, 98?104; p=0?0009).
Interpretation
Fetal valproate exposure has dose-dependent associations with reduced cognitive abilities across a range of domains at 6 years of age. Reduced right-handedness and verbal (vs non-verbal) abilities might be attributable to changes in cerebral lateralisation induced by exposure to antiepileptic drugs. The positive association of periconceptional folate with IQ is consistent with other recent studies.
Funding
US National Institutes of Health, UK Epilepsy Research Foundation.